

Elahe Ghasemi (MSc)¹
 Elaheh Ferdosi-Shahandashti
 (PhD)^{2, 3*}
 Mehdi Rajabnia (PhD)²
 Parisa Sabbagh (MSc)²
 Amirhosein Maali (MSc)^{4, 5}
 Azadeh Ferdosi-Shahandashti
 (MSc)⁶

1. Department of Biotechnology, Islamic Azad University, Damghan, Iran
2. Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3. Department of Medical Biotechnology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran
4. Student Research Committee, Pasteur Institute of Iran, Tehran, Iran
5. Department of Medical Biotechnology, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
6. Department of Microbiology, School of Sciences, Islamic Azad University, Ayatollah Amoli Branch, Amol, Iran

* Correspondence:

Elaheh Ferdosi-Shahandashti,
 Infectious Diseases and Tropical
 Medicine Research Center, Health
 Research Institute, Babol
 University of Medical Sciences,
 Babol, Iran

E-mail: elaheh.ferdosi@yahoo.com
 Tel: 0098 9113210431
 Fax: 0098 1132190181

Received: 29 Nov 2019

Revised: 23 April 2020

Accepted: 26 April 2020

Class I integrons among multidrug resistant *Enterobacter* spp. isolates from hospitalized patients in Babol, North of Iran

Abstract

Background: Multidrug resistance (MDR) in *Enterobacter* spp. has created therapeutic challenges all over the world. The present study was conducted for evaluating the prevalence of class I integron, determining the gene cassettes and antimicrobial resistance profile of *Enterobacter* spp. isolates from clinical samples in Babol, North of Iran.

Methods: During a 13-month period, 30 *Enterobacter* spp. isolates were collected from Ayatollah Rouhani Hospital, Babol, Iran. Various types of antimicrobial agents were used to determine the resistance pattern. Class I integron and associated gene cassettes were detected by PCR assay.

Results: The resistance rates to AP, CPM, CTX, TM, NI, IMI, AK, CIP and GM antimicrobials were 100%, 93.3%, 33.3%, 33.3%, 30%, 20%, 20%, 20% and 13.3%, respectively. The distribution results of *int* genes showed that 63.3% of isolates carried the *int1* genes. Also, the prevalence of *aadB*, *dfrA1*, *bla_{OXA30}* and *bla_{PSE1}* genes were estimated at 36.6%, 33.3%, 6.6% and 0%, respectively.

Conclusion: Our results showed that class I integrons have a widespread distribution among the *Enterobacter* spp. isolates and have clinical relevance to MDR isolates. The results confirmed the necessity for uninterrupted monitoring to prevent distribution of multidrug resistance among *Enterobacter* spp. strains in Iran.

Keywords: Class I integron, *Enterobacter*, Multidrug resistance (MDR).

Citation:

Ghasemi E, Ferdosi-shahandashti E, Rajabnia M, Sabbagh P, Maali A, Ferdosi-Shahandashti A. Class I integrons among multidrug resistant *Enterobacter* spp. isolates from hospitalized patients in Babol, North of Iran. Caspian J Intern Med 2021; 12(1): 65-69.

E*nterobacter* spp. are aerobic gram-negative bacilli from *Enterobacteriaceae* family (1). These organisms have three major species (*Enterobacter Cloacae*, *Enterobacter sakazaii* and *Enterobacter Aerogenes*). *Enterobacter* spp. are present in the environment and they are one of the most important opportunistic pathogen responsible for various hospitalized and community-acquired infections (2, 3), including pneumonia, bacteremia, septicemia, meningitis as well as the wound, urinary tract, respiratory tract and lower gastrointestinal infections (4, 5). The widespread and inappropriate use of antimicrobials applied for the treatment of bacterial infections, lead to a perilous increasing in resistant isolates and represents a great concern to the medical community (6-8). The acquisition of antimicrobial resistance in *Enterobacter* spp. may be related to mobile genetic elements (MGEs) such as plasmids, transposons and gene cassettes in integrons (8, 9). Integrons are conserved sequences carrying the antimicrobial resistance determinants while they are located within the gene cassettes (10-12). Integrons are constituted from three parts based on their conserved sequences (3'-CS and 5'-CS).

These genetic fragments are considered by the presence of a recombination site (*attI*), a promoter (*P_C*), and an *intI* gene (integrase) (13). Integrons are classified as four main classes through the type of integrase genes. Transferable class I integrons are the most prevalent among other classes (14). Class I integrons consist some resistance genes including AMEs (disinfectants and aminoglycoside-modifying enzymes), *sulI* gene (sulfonamide), *dfr* gene (dihydroflavonol- 4-reductase/trimethoprim), broad-spectrum b-lactamase and *qacED1* (tetravalent ammonium compounds) (15) and carry various gene cassettes, e.g. *aadB*, *dfrA1*, *bla_{OXA30}* and *bla_{PE1}*. Also, integrons are associated with MDR and play a critical role in the development of multidrug resistance (11). There are some reports dealing on the role of class I integrons in antibiotic resistance of *Enterobacter spp.*. The results of Mokracka *et al.* established the role of Class I integron gene cassettes in resistance patterns of patient-isolated *Enterobacter cloacae* (16).

The knowledge about antibiotic resistance and its mechanisms is a way to reduce the risk of antibiotic therapy failure. The aim of this study was to detect the dissemination of class I integrons and gene cassettes in clinical isolates of *Enterobacter spp.* from Babol, North of Iran.

Methods

Sampling and identification: In this cross-sectional study, 30 clinical isolates of *Enterobacter spp.* were collected from clinical samples of patients admitted with urinary tract

infections (UTI) at Ayatollah Rouhani Hospital, Babol, North of Iran. *Enterobacter spp.* were identified based on microbial bio-typing tests. All strains were stored in LuriaBertani broth (Merck, Germany) containing 20% glycerol at -80^o C for further use.

Antibiotic susceptibility test: According to the guidelines of Clinical and Laboratory Standards Institute (CLSI document M100-S25) (17), antimicrobial susceptibility tests were conducted on the Mueller-Hinton agar plates (Merck, Germany) through the standard disk agar diffusion method for antimicrobials, i.e. cefepime (CPM, 30 µg), gentamicin (GM, 10 µg), ciprofloxacin (CIP, 5 µg), imipenem (IMI 10 µg), amikacin (AK, 30 µg), cefotaxime (CTX, 30 µg), ampicillin (AP, µg), trimethoprim (TM, 5 µg) and nitrofurantoin (NI, 100 µg) (MAST Diagnostics, Merseyside, UK). *Escherichia coli* strain (ATCC 25922) was used as a positive quality control.

Polymerase chain reaction method: According to DNA purification kit (Roche, Germany) protocol, genomic DNA was extracted from expanded *Enterobacter spp.* colonies. The total volume of PCR reaction mixture was 25 µl, containing 0.7 µl of Taq DNA polymerase (5 IU/µl) (Amplicon Co., Denmark), 2.0 µl of PCR buffer, 1.0 µl of extracted DNA template, 0.5 µl of each primers (10 pmol), 0.6 µl MgCl₂ (50 mM), 0.6 µl dNTPs (10 mM), and 19.6 µl ddH₂O. Amplification was performed in a thermocycler (Corrbet, Australia) as mentioned (table 1).

Statistical Analysis: All statistical analysis was made by SPSS Version 16. The correlation of class I integrons and antibiotic resistance was examined by chi-square test.

Table 1: Oligonucleotide primers used for PCR amplification.

Gene	Sequence (5'-3')	Cycles No.		PCR condition			Product size(bp)	Reference
				Denaturation	Annealing	Extension		
<i>intI1</i>	F- TCTCGGGTAACATCAAGG	35	Temp	94 °C	53 °C	72 °C	243	(24)
	R- AGGAGATCCGAAGACCTC		Time	60 Sec	60 Sec	30 Sec		
<i>aadB</i>	F- GGGCGCGTCATGGAGGAGTT	35	Temp	94 °C	55 °C	72 °C	329	(25)
	R- TATCGCGACCTGAAAAGCGGC		Time	60 Sec	60 Sec	30 Sec		
<i>dfrA1</i>	F- GGAGTGCCAAAGGTGAACAGC	35	Temp	94 °C	60 °C	72 °C	367	(26)
	R- GAGGCGAAGTCTTGGGTA AAAAAC		Time	60 Sec	60 Sec	30 Sec		
<i>bla_{PE1}</i>	F- GGCAGGCAATCACACTCG	35	Temp	94 °C	50 °C	72 °C	153	(8)
	R- AATCAGGCTCAATACGGTCTAG		Time	30 Sec	60 Sec	60 Sec		
<i>bla_{OXA30}</i>	F- ATTATCTACAGCAGCGCCAGTGCATC	35	Temp	94 °C	50 °C	72 °C	716	(27)
	R- TTCGACCCCAAGTTTCTGTAAAGTGC		Time	30 Sec	60 Sec	30 Sec		

Results

Bacterial Isolation: In this study, 30 clinical isolates of *Enterobacter* were collected from the hospital-admitted patients from 12 (40%) males and 18 (60%) females.

Antibiotic Resistance Profile: In antibiogram screening, the resistance rates to AP, CPM, CTX, TM, NI, IMI, AK, CIP and GM antimicrobials were 100%, 93.3%, 33.3%, 33.3%, 30%, 20%, 20%, 20% and 13.3%, respectively (table 2). As our results, 93.33% of isolates contained MDR phenotype. The

highest resistance rate was related to AP and CPE antimicrobials and the highest susceptibility was related to GM and AK antimicrobials (table 3).

Class I integron and gene cassettes: *IntI* gene was detected in 63.3% (n=19) of *Enterobacter spp.* isolates. The prevalence of *dfrA1*, *aadB*, *bla-OXA30* and *blaPSE1* genes were estimated at 11 (36.6%) 10 (33.3%), 2 (6.6%) and 0 (0%), respectively (non-significant) (table 2).

Table2: Antibiotic resistance pattern of studied *Enterobacter* isolates according to integron positivity

Antibiotics	Total (n=30)			Integron Positive (n=19)		Integron Negative (n=11)		P<0.05
	R	I	S	R	S	R	S	
	No.(%)	No.(%)	No.(%)	No.(%)	No.(%)	No.(%)	No.(%)	
Ampicillin	30(100%)	0(0%)	0(0%)	19(100%)	0(0%)	11(100%)	0(0%)	0.181
Cefepime	28(93.3%)	2(6.66%)	0(0%)	19(100%)	0(0%)	10(90%)	1(9.1%)	0.181
Cefotaxime	10(33.3%)	5(16.6%)	15(50%)	8(42.1%)	11(57.9%)	6(54.5%)	5(45.5%)	0.510
Trimethoprim	10(33.3%)	1(3.3%)	19(63.3%)	6(31.6%)	13(68.6%)	5(45.5%)	6(54.5%)	0.447
Nitrofurantoin	9(30%)	6(20%)	15(50%)	9(47.4%)	10(52.6%)	6(54.5%)	5(45.5%)	0.705
Imipenem	6(20%)	3(10%)	21(70%)	5(26.3%)	14(73.7%)	4(36.4%)	7(63.6%)	0.563
Amikacin	6(20%)	0(0%)	24(80%)	4(21.1%)	15(78.9%)	2(18.2%)	9(81.8%)	0.850
Ciprofloxacin	6(20%)	9(30%)	15(50%)	8(42.1%)	11(57.9%)	7(63.3%)	4(36.4%)	0.256
Gentamicin	4(13.3%)	1(3.3%)	28(83.3%)	4(21.1%)	2(18.2%)	15(78.9%)	9(81.8%)	0.850

Table3: Multi Drugs Resistance profiles

Type of resistant	Pattern of antibiotic resistant	No. of isolates	Total
Resistant to 1 agent	AP	2	2
Resistant to 2 agents	AP-CPM	11	12
	AM-NI	1	
Resistant to 3 agents	CIP-AP-NI	2	6
	CPM-AP-NI	1	
	CPM-AP-AK	2	
	TM-CIP-AP	1	
Resistant to 4 agents	TM-CIP-CTX-AP	2	2
Resistant to 5 agents	TM-CIP-CTX-AP-NI	1	2
	CTX-CIP-AP-IMI-AK	1	
Resistant to 8 agents	TM-CPM-CTX-CIP-GM-AP-IMI-AK	1	4
	TM-CPM-CTX-CIP-GM-AP-IMI-NI	2	
	TM-CPM-CTX-CIP-GM -IMI-AK-NI	1	
Resistant to 9 agents	NI-IMI-AK-AP-GM-CIP-CTX-CPM-TM	2	2
Total	14	30	30

Discussion

In recent years, MDR *Enterobacter spp.* has been increasingly reported as a cause of MDR nosocomial infections (18, 19). Increase in number of MDR strains has many reasons, i.e. inappropriate administering of antibiotics or transferring of resistance genes through MGEs (including transposons (TEs), integrons (*int*), plasmids and bacteriophages) (20).

In agreement with our results, several studies established that antibiotic resistance in *Enterobacter spp.* has increased due to misuse, overuse and uncontrolled use of antimicrobials, so 93.33% of tested *Enterobacter spp.* indicated MDR phenotype. Also, Rizk *et al.* (2), showed that 85.7% of strains were MDR.

All of the strains were resistant to AP antimicrobial and 93.3% of strains were resistant to CPM antimicrobial. Also, 42.8% of MDR *E. coli* isolates, 90% of MDR *K. pneumoniae* isolates and 25% of MDR *Enterobacter spp.* carried class I integron. They reported a significant correlation between the GM antimicrobial resistance pattern and class I integron in MDR *E. coli* isolates.

The highest susceptibility to GM antimicrobial was estimated 13.3%. These data are similar to Mansuri *et al.*'s (2, 21). Of 30 *Enterobacter spp.* isolates, 19 (63.3%) strains carried the *intI* gene. Rizk *et al.*'s (2), Amin *et al.*'s (1) and Zheng *et al.*'s studies (22) showed that 28%, 47.4% and 77.8% of strains contain *intI* gene, respectively. These differences are due to the geographical distribution, type of organisms and source of infections; such finding was observed in foreign countries as well (23). The prevalence of *dfraI*, *aadB*, *bla_{OXA30}* and *bla_{PSE1}* gene cassettes were 36.6% (11), 33.3% (10), 6.6% (2) and 0% (0), respectively. Also, no significant correlations were found between these gene cassettes and integrons with antibiotic resistance.

Our results showed that class I integron has a widespread distribution among *Enterobacter spp.* isolates and have clinical relevance to MDR isolates. The findings emphasized that there is an urgent requirement for continuous surveillance to prevent more distribution of emerging multidrug resistance among *Enterobacter spp.* strains in Iran.

Finally, it can be concluded that distribution of class I integron in *Enterobacter spp.* isolates is very high among hospitalized samples as a high impact factor in occurrence of multidrug resistance. Therefore, the knowledge of resistance pattern in strains is helpful for the correction of antimicrobial administration and prevention of further antibiotic resistance.

Author contributions

P.S, M.R and E.F.Sh conceived the study; M.R, A.F.Sh, and E.F.Sh collected all data; A. M, P.S and E.F.Sh drafted the manuscript; and all authors commented on the drafts of the manuscript and approved the final draft of the paper.

Acknowledgments

The authors thank the Vice-Chancellery for Research and Technology of Babol University of Medical Sciences for the financial support.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest: All authors declare no conflict of interest.

References

1. Amin M, Dibachi S, Shahin M. Prevalence of class 1 integrons and plasmid-mediated qnr-genes among *Enterobacter* isolates obtained from hospitalized patients in Ahvaz, Iran. *Le Infez Med* 2017; 25: 351-7.
2. Rizk DE, El-Mahdy AM. Emergence of class 1 to 3 integrons among members of Enterobacteriaceae in Egypt. *Microb Pathog* 2017; 112: 50-6.
3. Sanders W, Sanders CC. *Enterobacter spp.*: pathogens poised to flourish at the turn of the century. *Clin Microbiol Rev* 1997; 10: 220-41.
4. Davin-Regli A, Pagès JM. *Enterobacter aerogenes* and *Enterobacter cloacae*; versatile bacterial pathogens confronting antibiotic treatment. *Front Microbiol* 2015; 6: 392.
5. Demir T, Baran G, Buyukguclu T, Sezgin FM, Kaymaz H. Pneumonia due to *Enterobacter cancerogenus* infection. *Folia Microbiol* 2014; 59: 527-30.
6. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. *Mayo Clin Proc* 2011; 86: 156-67.
7. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. *Clin Infec Dis* 2002; 35: 1505-11.
8. Akrami F, Shahandashti EF, Yahyapour Y, et al. Integron types, gene cassettes and antimicrobial resistance profile of *Acinetobacter baumannii* isolated from BAL samples in Babol, North of Iran. *Microb Pathog* 2017 ;109: 35-8.

9. Bennett PM. Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria. *Br J Pharmacol* 2008; 153: S347-S57.
10. Molana Z, Ferdosi Shahandashti E, Gharavi S, et al. Molecular investigation of class I integron in klebsiella pneumoniae isolated from intensive care unit (Shahid Beheshti Hospital of Babol; 2010). *J Babol Univ Med Sci* 2011; 13: 7-15. [in Persian]
11. Ahangarkani F, Rajabnia R, Shahandashti EF, Bagheri M, Ramez M. Frequency of class 1 integron in *Escherichia coli* strains isolated from patients with urinary tract infections in North of Iran. *Materia Sociomedica* 2015; 27: 10-2.
12. Asgharpour F, Rajabnia R, Shahandashti EF, et al. Investigation of class I integron in *Salmonella infantis* and its association with drug resistance. *Jundishapur J Microbiol* 20; 7: e10019.
13. Deylam Salehi M, Ferdosi-Shahandashti E, Yahyapour Y, et al. Integron-Mediated Antibiotic Resistance in *Acinetobacter baumannii* Isolated from Intensive Care Unit Patients, Babol, North of Iran. *BioMed Res Int* 2017;2017:7157923.
14. Shahandashti EF, Molana Z, Asgharpour F, Mojtahedi A, Rajabnia R. Molecular detection of Integron genes and pattern of antibiotic resistance in *Pseudomonas aeruginosa* strains isolated from intensive care unit, Shahid Beheshti Hospital, North of Iran. *Int J Mol Cell Med* 2012; 1: 209-17.
15. Deng Y, Bao X, Ji L, et al. Resistance integrons: class 1, 2 and 3 integrons. *Ann Clin Microbiol Antimicrob* 2015; 14: 45.
16. Mokracka J, Koczura R, Pawłowski K, Kaznowski A. Resistance patterns and integron cassette arrays of *Enterobacter cloacae* complex strains of human origin. *J Med Microbiol* 2011; 60: 737-43.
17. Paradowska D, Tomaszewski KA, Balajewicz-Nowak M, et al. Validation of the Polish version of the EORTC QLQ-CX24 module for the assessment of health-related quality of life in women with cervical cancer. *Eur J Cancer Care (Engl)* 2014; 23: 214-20.
18. Yu WL, Cheng HS, Lin HC, Peng CT, Tsai CH. Outbreak investigation of nosocomial *Enterobacter cloacae* bacteraemia in a neonatal intensive care unit. *Scand J Infect Dis* 2000; 32: 293-8.
19. Stoesser N, Sheppard A, Shakya M, et al. Dynamics of MDR *Enterobacter cloacae* outbreaks in a neonatal unit in Nepal: insights using wider sampling frames and next-generation sequencing. *J Antimicrob Chemother* 2015; 70: 1008-15.
20. Cantón R, Coque TM, Baquero F. Multi-resistant Gram-negative bacilli: from epidemics to endemics. *Curr Opin Infect Dis* 2003; 16: 315-25.
21. Molazadeh AR, Gholami MS, Shahi A, et al. Evaluation of antibiotic resistance pattern of isolated gram-negative bacteria from urine culture of hospitalized patients in different wards of Vali-Asr hospital in Fasa during the years 2012 and 2013. *J Fasa Univ Med Sci* 2014; 4: 275-83.[in Persian]
22. Zheng F, Sun J, Cheng C, Rui Y. Molecular characteristics of carbapenem-resistant gram-negative bacteria in southern China. *Microbial Drug Resist* 2015; 2: 178-85.
23. Vasilakopoulou A, Psychogiou M, Tzouveleakis L, et al . Prevalence and characterization of class 1 integrons in *Escherichia coli* of poultry and human origin. *Foodborne Pathogens Dis* 2009; 6: 1211-8.
24. Leverstein-Van Hall M, Paauw A, Box ATA, et al. Presence of integron-associated resistance in the community is widespread and contributes to multidrug resistance in the hospital. *J Clin Microbiol* 2002; 40: 3038-40.
25. Pazhani G, Chakraborty S, Fujihara K, et al. QRDR mutations, efflux system antimicrobial resistance genes in enterotoxigenic *Escherichia coli* isolated from an outbreak of diarrhoea in Ahmedabad, India. *Indian J Med Res* 2011; 134: 214-23.
26. Lapiere L, Cornejo J, Borie C, Toro C, San Martín B. Genetic characterization of antibiotic resistance genes linked to class 1 and class 2 integrons in commensal strains of *Escherichia coli* isolated from poultry and swine. *Microb Drug Resist* 2008; 14: 265-72.
27. De Vito D, Monno R, Nuccio F, et al. Diffusion and persistence of multidrug resistant *Salmonella* Typhimurium strains phage type DT120 in southern Italy. *BioMed Res Int* 2015;2015:265042..